మా గ్రూప్ ప్రతి సంవత్సరం USA, యూరప్ & ఆసియా అంతటా 3000+ గ్లోబల్ కాన్ఫరెన్స్ ఈవెంట్లను నిర్వహిస్తుంది మరియు 1000 కంటే ఎక్కువ సైంటిఫిక్ సొసైటీల మద్దతుతో 700+ ఓపెన్ యాక్సెస్ జర్నల్లను ప్రచురిస్తుంది , ఇందులో 50000 మంది ప్రముఖ వ్యక్తులు, ప్రఖ్యాత శాస్త్రవేత్తలు ఎడిటోరియల్ బోర్డ్ సభ్యులుగా ఉన్నారు.
ఎక్కువ మంది పాఠకులు మరియు అనులేఖనాలను పొందే ఓపెన్ యాక్సెస్ జర్నల్స్
700 జర్నల్స్ మరియు 15,000,000 రీడర్లు ప్రతి జర్నల్ 25,000+ రీడర్లను పొందుతున్నారు
Deepak Kumar Punna, Naveen Kumar Bathula
Introduction: The essential of cholesterol control is the use of HMG-COA inhibitors, but very few researches to date have directed on using what subjects accompanying nephrotic disease put oneself in the place of another cardiovascular occurrence.
Objective: To judge whether either HMG-COA inhibitors situation impacts the consequences of cardiovascular occurrence accompanying nephrotic condition.
Design: A sole center backward-looking reside case-control study resolved dossier from Vijaya Krishna multispecialty hospital, SVR kidney center, Area Hospital Suryapet.
Patients: Patient investigated accompanying nephrotic disease from January 1st, 2022 to December 31st, 2022
Measurement and main results: The research group contained 350 NS victims in total. At the judgment of the practical ending, 65 of these inmates were raised to have heart failure (CVD), and 2 CVD-free controls were contained by 1:2 corresponding accompanying common, age, and index period. To competition the criterion traits of the cases and controls (1:1), the weakness score corresponding was acted. The square test was run utilizing the patient's habit as an uncovering determinant, and a twofold logistic reversion study was approved to examine the friendship between the distance of HMG-COA inhibitors situation cure and cardiovascular occurrences. Additionally, subgroup studies for suitable determinants were completed activity. The square test told that HMG-COA inhibitors situation drug was essentially connected to a decrease in inmates' risk of CVD. NS abated as the distance of HMG-COA inhibitors situation raised (OR = 0.82 [95% CI 0.73– 0.89], p < 0.001).
Conclusions: For NS patients with dyslipidemia, HMG-COA inhibitor therapy may be used to decrease CVD risk, and extended treatment was associated with more significant risk reduction.